Goede and colleagues presented findings from the CLL11 trial, a large, randomized, phase 3 study of first-line chemoimmunotherapy regimens in patients with chronic lymphocytic lymphoma (CLL) who have comorbidities.
During the 2013 Annual Meeting of the American Society of Hematology, Drs Michael Hallek, John G Gribben, and Tait Shanafelt conducted an educational session titled, “Chronic Lymphocytic Leukemia: A New Treatment Era is Born.” Each physician presented various aspects of managing patients with CLL.
A definitive diagnosis of systemic lupus erythematosus (SLE) differentiating it from other rheumatic and autoimmune diseases can be challenging, because of a lack of definitive tests with sufficient sensitivity and specificity, as well as the absence of reliable biomarkers.
Systemic lupus erythematosus (SLE) often affects women of childbearing age. Pregnant women with SLE are known to be at increased risk of miscarriage and other complications during pregnancy.
Two important studies presented at the American College of Rheumatology annual meeting held in San Diego, California from October 25-30, 2013 analyzed the prevalence of systemic lupus erythematosus (SLE) and lupus nephritis in the US population, as well as the impact of SLE on employment and work productivity in American workers.
Blisibimod is a subcutaneously administered inhibitor of B-cell activating factor (BAFF) that has been evaluated in patients with systemic lupus erythematosus (SLE) in the phase 2b PEARL-SC trial and in an ensuing open-label extension study (NCT01305746).
Epratuzumab is an anti-CD22 monoclonal antibody that modulates B-cell activation and has demonstrated clinically relevant improvements in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE) in the phase 2b EMBLEM study (Wallace DJ, et al. Ann Rheum Dis. 2013 Jan 12. Epub ahead of print)
Patients with systemic lupus erythematosus (SLE) frequently require corticosteroids as standard therapy.
Large-scale phase 3 clinical trials have already demonstrated the clinical efficacy of belimumab (Benlysta) in patients with systemic lupus erythematosus (SLE), which served as the basis for the US Food and Drug Administration approval of this medication for adult patients with active, autoantibody-positive SLE who are receiving standard therapy.
Belimumab (Benlysta) is a human monoclonal antibody that inhibits B-lymphocyte stimulator that is approved by the US Food and Drug Administration for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
Page 3 of 4
Results 21 - 30 of 37
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME